Body Composition Peptides
Body composition peptides target fat metabolism through growth-hormone-related pathways, offering mechanisms of action fundamentally different from traditional weight loss approaches. The two compounds in this category, Tesamorelin and AOD-9604, both leverage the growth hormone system's fat-metabolizing properties but through distinct approaches: Tesamorelin stimulates the pituitary to produce endogenous GH (with full downstream effects), while AOD-9604 replicates only the C-terminal fragment responsible for lipolysis without affecting IGF-1 or glucose metabolism.
About Body Composition Peptides
This category addresses the growing recognition that body composition, the ratio of lean tissue to adipose tissue, is a more meaningful health metric than body weight alone. Visceral adipose tissue, in particular, is strongly linked to cardiovascular disease, insulin resistance, systemic inflammation, and metabolic syndrome. Both compounds show preferential effects on visceral fat, making them particularly relevant for metabolic health beyond cosmetic body composition goals. Tesamorelin holds FDA approval for HIV-associated lipodystrophy, providing a robust clinical evidence base including Phase III trial data demonstrating 15-18% visceral fat reduction. AOD-9604 has received FDA GRAS status and has Phase IIb clinical trial data. This level of clinical evidence distinguishes body composition peptides from many other research compounds in the peptide space. All protocols require specialist supervision with baseline and ongoing metabolic monitoring to ensure safe, effective outcomes integrated with proper nutrition and exercise programming. The pharmacological distinction between these two compounds is critical for understanding this category. Tesamorelin is a full GHRH analogue that stimulates the anterior pituitary to release growth hormone in pulsatile patterns that mimic physiological secretion. This means Tesamorelin produces a broad spectrum of GH-mediated effects beyond fat metabolism, including improved lipid profiles, potential cognitive benefits through IGF-1, enhanced sleep quality, and tissue maintenance effects. The clinical trade-off is that full GH axis stimulation requires more comprehensive monitoring including IGF-1 levels, glucose metabolism, and thyroid function. AOD-9604 takes a targeted approach by isolating amino acids 176 through 191 of the growth hormone molecule, the specific fragment responsible for lipolytic activity. This isolation means AOD-9604 produces fat metabolism effects without raising IGF-1, affecting blood glucose, or stimulating cell proliferation, resulting in a cleaner safety profile that requires less intensive monitoring. The choice between these approaches depends on whether the patient needs targeted fat metabolism support alone or comprehensive GH axis optimization.
Compounds in This Category
Tesamorelin
GHRH Analogue, Targeted Visceral Fat Reduction via Pulsatile GH Release
- Clinically Proven Visceral Fat Reduction
- Improved Lipid Profile
- Cognitive Function Support
- Physiological GH Optimization
AOD-9604
GH Fragment 176-191, Targeted Lipolysis Without Hormonal Side Effects
- Targeted Lipolysis
- No Hormonal Side Effects
- Lipogenesis Prevention
- FDA GRAS Safety Status
5-Amino-1MQ
NNMT Inhibitor, Targeting Cellular Energy Metabolism and Fat Regulation
- Enhanced Cellular Energy Expenditure
- NAD+ Biosynthesis Support
- Epigenetic Metabolic Regulation
- Non-Hormonal, Non-Stimulant Mechanism
Tesofensine
Triple Monoamine Reuptake Inhibitor, Modulating Appetite and Metabolic Signaling
Read ProfileTesofensine
Triple Monoamine Reuptake Inhibitor, Modulating Appetite and Metabolic Signaling
- Clinically Demonstrated Weight Reduction
- Appetite Regulation Through Central Mechanisms
- Metabolic Rate Enhancement
- Cardiometabolic Risk Factor Improvement
DHH-B (Dihydrohonokiol-B)
GABA-A Receptor Modulator, Bioactive Honokiol Derivative for Stress and Metabolic Research
Read ProfileDHH-B (Dihydrohonokiol-B)
GABA-A Receptor Modulator, Bioactive Honokiol Derivative for Stress and Metabolic Research
- Selective Anxiolytic Activity
- Stress-Metabolism Axis Research
- Antioxidant and Cytoprotective Properties
- Oral Bioavailability and CNS Penetration
MK-677 (Ibutamoren)
Non-Peptide Growth Hormone Secretagogue, Amplifying Endogenous GH and IGF-1 Output
Read ProfileMK-677 (Ibutamoren)
Non-Peptide Growth Hormone Secretagogue, Amplifying Endogenous GH and IGF-1 Output
- Sustained Growth Hormone Elevation
- Improved Body Composition
- Enhanced Sleep Quality
- Bone Metabolism Support
LGD-4033 (Ligandrol)
Selective Androgen Receptor Modulator, Targeting Muscle and Bone with Tissue Selectivity
Read ProfileLGD-4033 (Ligandrol)
Selective Androgen Receptor Modulator, Targeting Muscle and Bone with Tissue Selectivity
- Lean Mass Accretion
- Tissue-Selective Androgen Activity
- Bone Mineral Density Support
- Oral Bioavailability and Convenience
GW1516 (Cardarine)
PPAR-Delta Agonist, Reprogramming Metabolic Substrate Utilization and Endurance Capacity
Read ProfileGW1516 (Cardarine)
PPAR-Delta Agonist, Reprogramming Metabolic Substrate Utilization and Endurance Capacity
- Enhanced Endurance Capacity
- Improved Lipid Profiles
- Fat Metabolism Activation
- Anti-Inflammatory Metabolic Effects
Ipamorelin
Selective GH Secretagogue, Precision Growth Hormone Pulse Stimulation
- Selective GH Stimulation
- Body Composition Optimization
- Bone Mineral Density Support
- Recovery & Tissue Repair
Semaglutide
GLP-1 Receptor Agonist, Precision Modulation of Appetite and Glycemic Regulation
Read ProfileSemaglutide
GLP-1 Receptor Agonist, Precision Modulation of Appetite and Glycemic Regulation
- Body Composition Modulation
- Glycemic Regulation
- Appetite & Satiety Modulation
- Cardiovascular Risk Marker Improvement
Retatrutide
Triple Hormone Receptor Agonist, Simultaneous GIP/GLP-1/Glucagon Pathway Activation
Read ProfileRetatrutide
Triple Hormone Receptor Agonist, Simultaneous GIP/GLP-1/Glucagon Pathway Activation
- Superior Body Weight Reduction
- Increased Energy Expenditure
- Hepatic Fat Reduction
- Comprehensive Cardiometabolic Improvement
Tirzepatide
Dual GIP/GLP-1 Receptor Agonist, Twincretin Technology for Metabolic Optimization
Read ProfileTirzepatide
Dual GIP/GLP-1 Receptor Agonist, Twincretin Technology for Metabolic Optimization
- Dual Pathway Glycemic Control
- Significant Body Composition Effects
- Favorable Fat Distribution Modulation
- Hepatic & Cardiovascular Marker Improvement
Somatropin (HGH)
Recombinant Human Growth Hormone, Direct Somatotropic Axis Supplementation
Read ProfileSomatropin (HGH)
Recombinant Human Growth Hormone, Direct Somatotropic Axis Supplementation
- Body Composition Optimization
- Connective Tissue & Collagen Support
- Bone Mineral Density Maintenance
- Metabolic & Recovery Support
CI Blend Pen
Synergistic Growth Hormone Optimization, CJC-1295 + Ipamorelin in a Precision Auto-Injector
Read ProfileCI Blend Pen
Synergistic Growth Hormone Optimization, CJC-1295 + Ipamorelin in a Precision Auto-Injector
- Synergistic Growth Hormone Optimization
- Clean Selectivity Profile
- Body Composition & Recovery Support
- Precision Pen Delivery
TCI Blend Pen
Triple-Action Growth Hormone Amplification, Tesamorelin + CJC-1295 + Ipamorelin in a Single Pen
Read ProfileTCI Blend Pen
Triple-Action Growth Hormone Amplification, Tesamorelin + CJC-1295 + Ipamorelin in a Single Pen
- Triple-Pathway Growth Hormone Optimization
- FDA-Studied Tesamorelin Component
- Selective Hormone Profile
- Comprehensive Metabolic Support
Cagrilintide
Long-Acting Amylin Analogue, Next-Generation Appetite and Metabolic Regulation
Read ProfileCagrilintide
Long-Acting Amylin Analogue, Next-Generation Appetite and Metabolic Regulation
- Clinically Significant Weight Reduction
- Novel Appetite Regulation Pathway
- Improved Glycemic Control
- Convenient Once-Weekly Dosing
Category Comparison Matrix
| Product | Primary Mechanism | GH Axis Effect | IGF-1 Impact | Blood Glucose Effect | Clinical Evidence Level |
|---|---|---|---|---|---|
| Tesamorelin | GHRH Agonist → Full Pulsatile GH Release | Full pituitary stimulation | Increases IGF-1 | May affect glucose metabolism | FDA-Approved (Phase III trials) |
| AOD-9604 | GH Fragment 176-191 → Isolated Lipolysis | No pituitary stimulation | No IGF-1 change | No effect on glucose | FDA GRAS + Phase IIb trials |
| Ipamorelin | Ghrelin Receptor Agonist (GHS-R1a) | 1-2 weeks | 8-12 weeks | Subcutaneous | GH release/lean mass |
| MK-677 | Non-Peptide GH Secretagogue | 1-2 weeks | 8-16 weeks | Oral | GH/IGF-1 elevation/appetite |
| LGD-4033 | Selective Androgen Receptor Modulator | 1-2 weeks | 8-12 weeks | Oral | Lean mass/strength |
| GW1516 | PPAR-delta Agonist | 1-2 weeks | 8-12 weeks | Oral | Endurance/fat oxidation |
| 5-Amino-1MQ | NNMT Inhibitor | 2-4 weeks | 8-12 weeks | Oral | Fat metabolism/NAD+ preservation |
| Tesofensine | Triple Monoamine Reuptake Inhibitor | 1-2 weeks | 12-24 weeks | Oral | Appetite suppression/weight loss |
| DHH-B | GABA-A Receptor Modulation | 1-2 weeks | 4-8 weeks | Oral | Cortisol reduction/stress management |
Choosing Between Body Composition Peptide Compounds
The choice between Tesamorelin and AOD-9604 depends on metabolic profile, health goals, risk tolerance, and willingness to engage in comprehensive monitoring. A specialist would evaluate several factors to determine which compound best matches the clinical situation. Tesamorelin is typically preferred when the patient seeks comprehensive metabolic optimization beyond isolated fat loss. Its full GH axis stimulation provides benefits across multiple body systems: improved lipid profiles with reduced triglycerides and improved HDL ratios, potential cognitive enhancement through IGF-1 signaling, improved sleep architecture, and tissue maintenance effects. Patients with documented GH decline confirmed through stimulation testing or low IGF-1 levels are particularly strong candidates for Tesamorelin. However, Tesamorelin requires more intensive monitoring including quarterly IGF-1 levels, fasting glucose, and thyroid panels to ensure metabolic safety. AOD-9604 is typically preferred when isolated fat metabolism support is the primary goal and the patient wants to avoid GH axis stimulation. Its clean safety profile with no effect on IGF-1 or glucose metabolism makes it suitable for patients who have contraindications to full GH stimulation, those with pre-diabetic glucose profiles who cannot tolerate potential glucose effects, and patients who prefer simpler monitoring protocols. AOD-9604 is also preferred in patients for whom the potential proliferative effects of IGF-1 elevation represent an unacceptable risk. Both compounds work optimally when combined with structured nutrition and exercise programming. Administering AOD-9604 during fasted states, typically first thing in the morning before food intake, optimizes its lipolytic effects by aligning compound activity with the body's natural fasted metabolic state. Tesamorelin's evening administration aligns with the natural nocturnal GH pulse, amplifying physiological secretion patterns. A specialist would design administration timing and lifestyle integration recommendations specific to your daily routine and metabolic goals.
Safety Considerations & Contraindications for Body Composition Peptides
Body composition peptides interact with growth hormone pathways and metabolic systems, creating specific contraindication profiles that must be evaluated before initiating any protocol. The distinction between Tesamorelin's full GH axis stimulation and AOD-9604's isolated lipolytic mechanism means their contraindication profiles differ significantly. Tesamorelin is contraindicated in individuals with active malignancies, particularly those with hormone-sensitive cancers, as its IGF-1 elevation can promote tumor cell proliferation. Patients with pituitary tumors or conditions affecting pituitary function should not use GHRH agonists. Uncontrolled diabetes represents a relative contraindication, as GH can transiently impair insulin sensitivity and worsen glycemic control. Patients with diabetic retinopathy specifically should avoid Tesamorelin due to the theoretical risk of IGF-1 promoting retinal neovascularization. Pregnancy is an absolute contraindication as GH axis modulation could affect fetal development. AOD-9604 has a more favorable contraindication profile due to its isolated mechanism. Because it does not affect IGF-1 or glucose metabolism, many of the contraindications specific to full GH axis stimulation do not apply. However, individuals with known hypersensitivity to growth hormone fragments should avoid the compound. AOD-9604 has emerging research in cartilage regeneration contexts, but individuals with joint conditions should be aware that this application remains investigational. Both compounds require caution in individuals with eating disorders, as combining peptide-mediated fat metabolism with disordered eating behaviors could produce dangerous metabolic states. Patients with a BMI below the healthy range should not use fat metabolism compounds. Individuals taking thyroid medications may need dosage adjustments when using Tesamorelin, as GH can affect thyroid hormone metabolism. Corticosteroid users should be aware that chronic corticosteroid use can suppress the GH axis, potentially limiting Tesamorelin's effectiveness while also complicating metabolic monitoring. specialist monitoring for body composition protocols should include baseline and quarterly body composition analysis via DEXA scan, metabolic panels, fasting glucose, and for Tesamorelin users specifically, IGF-1 levels and thyroid function tests.
Quality Guide: Body Composition Peptide Quality Standards
Body composition peptides require specific quality considerations related to their growth-hormone-derived structures and the precision required for accurate metabolic dosing. Understanding these quality markers helps ensure the compound being used will produce results consistent with published clinical research. Tesamorelin is a forty-four amino acid peptide, making it one of the more complex compounds to synthesize accurately. Its structure includes a trans-3-hexenoic acid modification at the N-terminus that is essential for its enhanced binding affinity to GHRH receptors and its extended half-life compared to native GHRH. Quality verification must confirm both the peptide sequence accuracy and the presence of this modification through mass spectrometry analysis. Without the modification, the compound would behave like native GHRH with a half-life of only minutes, rendering it clinically impractical at standard dosing intervals. AOD-9604 is a shorter peptide fragment of sixteen amino acids with a disulfide bond between cysteine residues that is essential for maintaining the three-dimensional structure required for biological activity. Quality testing must verify both sequence accuracy and proper disulfide bond formation, as incorrectly folded peptide with mismatched or absent disulfide bonds would have significantly reduced or absent lipolytic activity. The peptide's relatively small size makes synthesis straightforward, but the disulfide bond adds a quality control step that distinguishes properly manufactured product from inferior alternatives. Both compounds require precise concentration measurement for accurate dosing, as the therapeutic window for body composition peptides involves specific microgram quantities that must be reliably delivered. Each vial should contain a verified quantity of lyophilized peptide with documented reconstitution instructions for achieving the target concentration. Overconcentrated or underconcentrated preparations compromise dosing accuracy and clinical outcomes. High-quality body composition peptides undergo comprehensive quality testing including HPLC purity analysis, mass spectrometry identity confirmation, endotoxin testing, and sterility verification. Temperature-controlled logistics should ensure temperature-sensitive compounds maintain stability throughout transit, and certificates of analysis provide batch-specific documentation for a specialist's records.
Frequently Asked Questions
Body composition peptides target fat metabolism through growth-hormone-related mechanisms rather than appetite suppression, thermogenesis, or nutrient absorption blocking. Tesamorelin stimulates pulsatile GH release for enhanced lipolysis, while AOD-9604 directly activates fat-burning enzymes. These mechanisms preserve lean tissue while reducing fat, improving body composition rather than simply reducing scale weight.
Both Tesamorelin and AOD-9604 are compounds studied in clinical research, typically requiring qualified medical supervision. Growth-hormone-related compounds require baseline metabolic assessment including body composition analysis, fasting glucose, lipid panel, and hormonal markers. Ongoing monitoring ensures metabolic safety and optimizes protocol effectiveness.
Tesamorelin provides broader GH benefits (body composition + cognitive + recovery) but affects IGF-1 and glucose metabolism, requiring more monitoring. AOD-9604 provides isolated fat-metabolic effects without IGF-1 or glucose changes, making it simpler to manage. A specialist would recommend based on metabolic profile, health goals, and any contraindications.
No. Body composition peptides enhance the body's fat metabolism mechanisms but work best when integrated with proper nutrition and regular exercise. They are not substitutes for lifestyle modification. A specialist would typically recommend concurrent diet and exercise optimization to maximize results and ensure sustainable body composition improvements.
Fat metabolism changes are gradual. Tesamorelin clinical trials measured significant visceral fat reduction over 12-26 weeks. AOD-9604 results typically become measurable after 6-8 weeks with protocols running 12-20 weeks. Medical-grade body composition analysis (DEXA scan) provides more accurate progress tracking than scale weight, which can be misleading if lean tissue is maintained while fat decreases.
Interested in Body Composition Peptides?
A specialist can help you understand which compounds may be relevant to your health goals.
Speak with a Specialist Free initial consultation. No obligation.Explore Other Categories
Recovery Peptides
Accelerate healing and tissue regeneration
Longevity Peptides
Target the mechanisms of biological aging
Cognitive Peptides
Enhance neural performance and clarity
Sexual Wellness Peptides
Restore vitality and intimate wellness
Sleep & Circadian Peptides
Regulate circadian rhythm and deep sleep
Immune Peptides
Modulate and strengthen immune defense
Reviewed by the Peptide Science Thailand Editorial Team.
Last reviewed: March 1, 2026